Market Place
Sourcing Support
Sun Pharma gets USFDA nod to market generic medication
10 Feb 2023 //
ECONOMIC TIMES
The top 10 all-time biggest-selling drugs by 2024
15 Aug 2019 //
FIERCE PHARMA
Revlimid (Lenalidomide) : Celgene Corporation vs. Apotex Inc.
27 Feb 2019 //
PATENT LITIGATION
Starboard Value has 1M -share stake in Bristol-Myers has met with management
22 Feb 2019 //
CNBC
Pomalyst (Pomalidomide) : Celgene Corp. vs. Hetero Drugs
30 Jan 2019 //
PATENT LITIGATION
Abraxane (Protein-bound paclitaxel): Celgene Corp. vs. HBT Labs
20 Dec 2018 //
PATENT LITIGATION
Pomalyst (Pomalidomide): Celgene Corporation vs. Mylan
24 Nov 2018 //
PATENT LITIGATION
Daliresp (Roflumilast) : AstraZeneca vs. Alkem
24 Nov 2018 //
PATENT LITIGATION
AMITIZA® (lubiprostone) : Sucampo Pharmaceuticals vs. Sun Pharmaceutical
31 Oct 2018 //
PATENT LITIGATION
Pomalyst (Pomalidomide) : Celgene Corp. vs. Breckenridge Pharma
19 Oct 2018 //
PATENT LITIGATION
Pomalyst (Pomalidomide) : Celgene Corp. vs. Teva Pharmaceuticals
02 Oct 2018 //
PATENT LITIGATION
Pomalyst (Pomalidomide): Celgene vs. Hetero Drugs Ltd.
21 Sep 2018 //
PATENT LITIGATION
Generics group says branded drugmakers blocking $13B in annual savings
06 Sep 2018 //
BIOPHARMA DIVE
Thalomid (thalidomide) : Celgene Corp. v. West-Ward Pharmaceutical International
03 Sep 2018 //
PATENT LITIGATION
Revlimid® (Lenalidomide): Celgene Corporation v. Sun Pharmaceutical Global FZE et al
18 Jul 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Pharmascience Inc.
16 Jul 2018 //
PATENT LITIGATION
Revlimid® (Lenalidomide): Celgene Corporation v. Lotus Pharmaceutical Co., Alvogen Group, Inc.
16 Jul 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Sandoz Inc.
16 Jul 2018 //
PATENT LITIGATION
Gilenya patent decision gives MS market a reprieve
14 Jul 2018 //
BIOPHARMA DIVE
OTEZLA® (apremilast): Celgene Corporation v. Aurobindo Pharma Limited
11 Jul 2018 //
PATENT LITIGATION
OTEZLA® (apremilast): Celgene Corporation v. Aurobindo Pharma Limited, et al.
09 Jul 2018 //
PATENT LITIGATION
OTEZLA® (apremilast): Celgene Corporation v. Amneal Pharmaceuticals Llc
04 Jul 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Cipla Limited
29 Jun 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Unichem Laboratories, Limited
29 Jun 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Alkem Laboratories Ltd.
29 Jun 2018 //
PATENT LITIGATION
Otezla® (apremilast): Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc.
29 Jun 2018 //
PATENT LITIGATION
Otezla (apremilast): Celgene Corporation v. Shilpa Medicare Ltd.
29 Jun 2018 //
PATENT LITIGATION
Pomalyst® (Pomalidomide Capsules) : Celgene Corporation v. Synthon
21 Jun 2018 //
PATENT LITIGATION
FDA Calls Out Pharma Cos for Blocking Requests from Generic Manufacturers
18 May 2018 //
BIOSPACE
FDA tries to shame drugmakers over tactics that delay generics
18 May 2018 //
FIERCE PHARMA
Who’s delaying generic competition? FDA publishes list of drugmakers
17 May 2018 //
ENDPTS
FDA ‘names and shames’ generic-blocking pharma companies
17 May 2018 //
PMLIVE
How A Drugmaker Gamed The System To Keep Generic Competition Away
17 May 2018 //
NPR
Revlimid® (Lenalidomide) : Celgene Corporation v. Zydus Pharma (USA)
27 Apr 2018 //
PATENT LITIGATION
Revlimid®(Lenalidomide) : Celgene Corporation v. Dr. Reddy`s Laboratories
12 Apr 2018 //
PATENT LITIGATION
Generics, mergers and Teva’s woes: Agilent talks pharma opportunities
16 Feb 2018 //
IN PHARMATECHNOLOGIST
Brain damage cases force an FDA hold on Bellicum’s lead cell therapy
31 Jan 2018 //
ENDPTS
Celgene Settlement With Actavis Allows Abraxane Generics In 2022
26 Jan 2018 //
PHARMAINTELLIGENCE
Revlimid®(Lenalidomide): Celgene Corporation V. Apotex
11 Jan 2018 //
PATENT LITIGATION
Cancer patient sues Celgene for thwarting generic versions of its pricey meds
15 Jun 2017 //
STATNEWS
Pomalyst® (Pomalidomide ): Celgene Corporation V. Par Pharmaceutical & Teva
04 May 2017 //
PATENT LITIGATION
Revlimid (Lenalidomide): Celgene v. Zydus Pharmaceuticals & Cadila Healthcare
12 Apr 2017 //
PATENT LITIGATION
Angry cancer patient sues Celgene for 500% jump in Revlimid cost
16 Jun 2016 //
FIERCE PHARMA
Celgene to allow sale of generic Revlimid before patent expiry
24 Dec 2015 //
REUTERS
Pharma`s new patent worry by the numbers: No `IP death squad` here, analyst says
04 Sep 2015 //
FIERCE PHARMA
